BRIEF published on 06/02/2026 at 14:35, 3 months 15 days ago Inventiva Resumes Trading on Euronext Paris Euronext Paris Debt Financing Trading Resumption Inventiva MASH Treatment
PRESS RELEASE published on 06/02/2026 at 14:30, 3 months 15 days ago Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris Inventiva announces trading resumption of its ordinary shares on Euronext Paris following Debt Financing Transaction and ADS Offering Euronext Paris Ordinary Shares Clinical-Stage Biopharmaceutical Trading Resumption Inventiva
BRIEF published on 06/02/2026 at 07:35, 3 months 15 days ago Temporary suspension of Inventiva shares on Euronext Paris Euronext Paris Funding Nasdaq Inventiva Temporary Suspension
BRIEF published on 06/02/2026 at 07:35, 3 months 15 days ago Inventiva Halts Trading of Ordinary Shares on Euronext Paris Euronext Paris Trading Halt Inventiva MASH Treatment Nadsaq
PRESS RELEASE published on 06/02/2026 at 07:30, 3 months 15 days ago Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris for a proposed financing transaction. Trading to resume after communication Euronext Paris Trading Halt Clinical Trial Inventiva Metabolic Dysfunction
BRIEF published on 05/26/2026 at 22:05, 3 months 22 days ago Inventiva Announces its First Quarter 2026 Financial Results Financial Results Treasury Biopharmaceutical Inventiva NATiV3
PRESS RELEASE published on 05/26/2026 at 22:00, 3 months 22 days ago Inventiva Reports 2026 First Quarter Financial Information¹ Inventiva reports first quarter 2026 financial information, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million. Explore company's financial results and upcoming milestones Financial Information Inventiva NATiV3 Cash Equivalents Short-term Deposits
BRIEF published on 05/21/2026 at 22:05, 3 months 27 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva Lanifibranor MASH Treatment Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 3 months 27 days ago Inventiva at the 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva MASH Lanifibranor Jefferies Conference
PRESS RELEASE published on 05/21/2026 at 22:00, 3 months 27 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Inventiva to present at 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain to speak on June 3, 2026, about MASH therapies Clinical-Stage Biopharmaceutical Inventiva Lanifibranor 2026 Jefferies Conference MASH Therapies
Published on 09/18/2026 at 00:25, 23 minutes ago CoTec Holdings Corp. Announces Initial Closing of Private Placement of Unsecured Convertible Debentures
Published on 09/17/2026 at 22:15, 2 hours 33 minutes ago Rocky Shore Gold Announces Non-Brokered Private Placement
Published on 09/17/2026 at 22:15, 2 hours 33 minutes ago Vanta Attends 2026 All-In Summit in Los Angeles, a Leading Gathering of Business, Investment and Industry Leaders
Published on 09/17/2026 at 22:05, 2 hours 43 minutes ago Loop Industries Forms Strategic Alternatives Committee to Maximize Shareholder Value
Published on 09/17/2026 at 15:55, 8 hours 53 minutes ago Empress Announces Agreement to Acquire Tongon Gold Stream and Secures Debt Financing
Published on 09/17/2026 at 19:00, 5 hours 47 minutes ago Max Verstappen Passes All 100 Karts in 14 Laps in Red Bull's Max vs 100
Published on 09/17/2026 at 18:58, 5 hours 49 minutes ago EQS-Adhoc: H2APEX Group SCA: General Partner of H2APEX Group SCA resolves to prepare for the transfer of its stock exchange listing from the Regulated Market (Prime Standard) to the Scale segment of the Frankfur
Published on 09/17/2026 at 18:25, 6 hours 22 minutes ago Magentic raises $18M to build the AI workforce for the physical world
Published on 09/17/2026 at 18:10, 6 hours 37 minutes ago A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%
Published on 09/17/2026 at 17:46, 7 hours 1 minute ago RBI categorically denies the allegations of short-seller report
Published on 09/17/2026 at 17:40, 7 hours 8 minutes ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
Published on 09/16/2026 at 17:45, 1 day 7 hours ago Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 1 day 17 hours ago bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
